Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Prior Placebo

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    7,054 result(s) found for: Prior Placebo. Displaying page 7 of 353.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    EudraCT Number: 2020-002848-22 Sponsor Protocol Number: MV-004 Start Date*: 2020-12-03
    Sponsor Name:Meissa Vaccines Inc.
    Full Title: A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Prophylactic Efficacy of MV-012-968 Against Respiratory Syncytial Virus (RSV) Infection in the Virus Challe...
    Medical condition: Respiratory Syncytial Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2006-003371-13 Sponsor Protocol Number: IM101084 Start Date*: 2007-07-17
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3, Multi-Center, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy with Abatacept in Subjects with Active Crohn’s Diseas...
    Medical condition: Crohn's disease, NOS
    Disease: Version SOC Term Classification Code Term Level
    8.1 10011401 Crohn's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) NL (Prematurely Ended) GB (Prematurely Ended) BE (Completed) IE (Completed) DK (Prematurely Ended) CZ (Completed) PL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: Removed from public view
    EudraCT Number: 2014-002742-42 Sponsor Protocol Number: 2013DM19 Start Date*: 2014-12-23
    Sponsor Name:University of Dundee/ NHS Tayside
    Full Title: Research into the Effect Of SGLT2 inhibition on left ventricular Remodelling in patients with heart failure and diabetes Mellitus
    Medical condition: Type 2 diabetes and Heart Failure
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-007074-29 Sponsor Protocol Number: VP-VSF-173-2001 Start Date*: 2007-04-20
    Sponsor Name:Vanda Pharmaceuticals Inc.
    Full Title: A randomized, double-blind, placebo-controlled, parallel study to investigate the efficacy and safety of three oral doses of VSF-173 (50 mg , 100 mg, and 200 mg total daily dose; given twice, 4 hou...
    Medical condition: excessive sleepiness
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015595 Excessive daytime sleepiness LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-005407-38 Sponsor Protocol Number: MK-3475-B49 Start Date*: 2021-08-17
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate Hormone Receptor-Positi...
    Medical condition: Treatment of patients with HR+/HER2- locally recurrent inoperable or MBC whose tumors express PD-L1
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10072740 Locally advanced breast cancer LLT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10083232 HER2 negative breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) FR (Trial now transitioned) NL (Trial now transitioned) PL (Trial now transitioned) DE (Trial now transitioned) PT (Trial now transitioned) IT (Trial now transitioned) GR (Trial now transitioned) HU (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-004194-12 Sponsor Protocol Number: CS-BM32-nasal-001 Start Date*: 2012-10-23
    Sponsor Name:Medizinische Universität Wien, HNO Klinik
    Full Title: The effect of BM32, a recombinant hypoallergenic vaccine for immunotherapy of grass pollen allergy, on immunoglobulin levels in nasal secretions of patients suffering from seasonal allergic rhinitis
    Medical condition: Grass pollen allergy
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2018-003083-30 Sponsor Protocol Number: PLAQHV Start Date*: 2019-01-31
    Sponsor Name:UZ Leuven
    Full Title: The effect of hydroxychloroquine sulphate on hedonic food intake, appetite-related sensations and gastrointestinal hormone release in healthy female subjects
    Medical condition: The study is meant to have a better understanding in obesity and how we can prevent/cure it. Therefore, the product will first be tested in healthy, lean volunteers.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-017415-16 Sponsor Protocol Number: AFCT-14/2009 Start Date*: 2010-07-26
    Sponsor Name:Dr. August Wolff GmbH & Co KG Arzneimittel
    Full Title: A Phase III, single-center, randomized, double-blind, parallel group, placebo-controlled study of Alpicort F in the treatment of chemotherapy induced alopecia in women
    Medical condition: Chemotherapy induced alopecia in women
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-002185-13 Sponsor Protocol Number: clebopride2019 Start Date*: 2019-10-03
    Sponsor Name:KU Leuven - TARGID
    Full Title: A Randomized, Double Blind, Placebo Controlled, Crossover Trial of Clebopride vs Placebo in the Treatment of Clinically Suspected Rumination.
    Medical condition: rumination syndrome
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-002761-63 Sponsor Protocol Number: HPV-301 Start Date*: 2018-04-16
    Sponsor Name:Inovio Pharmaceuticals, Inc.
    Full Title: A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF VGX-3100 DELIVERED INTRAMUSCULARLY FOLLOWED BY ELECTROPORATION WITH CELLECTRA™ 5PSP FOR THE TREATMENT OF HPV-16 AND/OR H...
    Medical condition: HPV-16 AND/OR HPV-18 RELATED HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS (HSIL) OF THE CERVIX
    Disease: Version SOC Term Classification Code Term Level
    21.1 10022891 - Investigations 10064328 Human papilloma virus test positive PT
    21.1 100000004872 10066237 Cervical high grade squamous intraepithelial lesion LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) LT (Completed) FI (Completed) DE (Completed) CZ (Prematurely Ended) ES (Completed) PT (Completed) PL (Completed) SK (Completed) BE (Completed) NL (Ongoing) EE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-004853-59 Sponsor Protocol Number: EX6018-4758 Start Date*: 2021-08-16
    Sponsor Name:Novo Nordisk A/S
    Full Title: ZEUS - Effects of ziltivekimab versus placebo on cardiovascular outcomes in participants with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation
    Medical condition: Atherosclerotic cardiovascular disease Chronic kidney disease Systemic inflammation
    Disease: Version SOC Term Classification Code Term Level
    26.0 10047065 - Vascular disorders 10051615 Atherosclerotic cardiovascular disease LLT
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    20.1 10022891 - Investigations 10067394 hs-CRP increased LLT
    21.0 10022891 - Investigations 10011418 CRP increased LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Trial now transitioned) SK (Trial now transitioned) DE (Trial now transitioned) NL (Ongoing) SE (Trial now transitioned) PL (Trial now transitioned) GR (Trial now transitioned) DK (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) BG (Trial now transitioned) PT (Trial now transitioned) IT (Trial now transitioned) HU (Trial now transitioned) CZ (Trial now transitioned) LV (Trial now transitioned) HR (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-001953-28 Sponsor Protocol Number: EFC15804 Start Date*: 2019-07-01
    Sponsor Name:Sanofi-aventis Recherche & Développement
    Full Title: A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients with Moderate-to-severe Chronic Obstr...
    Medical condition: Chronic obstructive pulmonary disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) DK (Completed) FI (Completed) CZ (Completed) HU (Completed) PL (Completed) SK (Completed) BG (Completed) IT (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2012-000928-18 Sponsor Protocol Number: PROMESA Start Date*: 2013-11-21
    Sponsor Name:Hospital of the Ludwig-Maximilians-University of Munich
    Full Title: Double blind, randomised, prospective placebo controlled parallel group phase III study to investigate the Effect of EGCG supplementation on disease progression of patients with Multiple System Atr...
    Medical condition: Progression of patients with Multiple System Atrophy (MSA)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-003224-31 Sponsor Protocol Number: ACE-536-B-THAL-001 Start Date*: 2016-03-14
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Determine the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell...
    Medical condition: Adults who require regular Red Blood Cell (RBC) transfusions due to Beta-Thalassemia.
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004850 10054658 Thalassemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Prematurely Ended) BG (Completed) GR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-000898-83 Sponsor Protocol Number: ADN016 Start Date*: 2021-11-10
    Sponsor Name:ADIENNE SA
    Full Title: A phase II, randomized, double-blind, placebo-controlled, two-period, crossover trial to assess the efficacy and safety of begelomab in combination with standard steroid and/or immunosuppressant th...
    Medical condition: Dermatomyositis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10012503 Dermatomyositis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-004117-40 Sponsor Protocol Number: MK-3475-641 Start Date*: 2020-03-05
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) ...
    Medical condition: Metastatic Castration-Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) AT (Trial now transitioned) GB (GB - no longer in EU/EEA) PL (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing) IE (Trial now transitioned) IT (Trial now transitioned) CZ (Ongoing) HU (Trial now transitioned) BG (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-020604-29 Sponsor Protocol Number: H6D-CR-LVIW(a), Addendum 1 u.4 Start Date*: 2010-11-05
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: A Phase 3b,randomized,double-blind,placebo-controlled parallel-design study to evaluate the efficacy and safety of tadalafil coadministered with finasteride for 6 months in men with lower urinary ...
    Medical condition: Benign Prostatic Hyperplasia (BPH)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10004446 Benign prostatic hyperplasia LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) FR (Completed) BE (Completed) IT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2017-004738-27 Sponsor Protocol Number: A011-09 Start Date*: 2018-08-15
    Sponsor Name:Acceleron Pharma Inc.
    Full Title: A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study to Compare the Efficacy and Safety of Sotatercept (ACE-011) Versus Placebo When Added to Standard of Care for the Treatment of Pulmonar...
    Medical condition: Pulmonary Arterial Hypertension (PAH)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10077739 Pulmonary arterial hypertension WHO functional class I LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-005076-41 Sponsor Protocol Number: E7001-H002 Start Date*: 2006-11-14
    Sponsor Name:Hvidovre Hospital
    Full Title: Effect of nasal GLP-1 versus placebo on fasting state and postprandial hyperglycaemia in type 2 diabetes. A single centre, prospective, placebo controlled clinical trial evaluating efficacy and sa...
    Medical condition: Diabetes Mellitus type 2
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002041-59 Sponsor Protocol Number: DP10018 Start Date*: 2015-09-11
    Sponsor Name:Acacia Pharma Ltd
    Full Title: Randomised, double-blind, placebo-controlled study of APD421 (amisulpride for IV injection) as treatment of established post-operative nausea and vomiting, in patients who have had no prior prophyl...
    Medical condition: Post-operative nausea and vomiting
    Disease: Version SOC Term Classification Code Term Level
    18.1 10022117 - Injury, poisoning and procedural complications 10066962 Procedural nausea PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jun 27 01:11:00 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA